SPBC4F6.12 Antibody

What is SPBC4F6.12 and what is its significance in S. pombe research?

SPBC4F6.12, also known as pxl1 (paxillin-like protein 1), is a LIM domain-containing protein found in Schizosaccharomyces pombe (fission yeast) . As a paxillin-like protein, it plays critical roles in cytoskeletal organization, cell adhesion, and signal transduction pathways. The protein contains LIM domains, which are zinc finger structures that mediate protein-protein interactions and are found in various proteins involved in cytoskeletal organization. Understanding SPBC4F6.12 function contributes to our broader knowledge of conserved cellular processes across eukaryotes, from yeast to humans.

What are the recommended applications for SPBC4F6.12 antibodies?

Based on validated applications, SPBC4F6.12 antibodies have been successfully employed in ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot techniques . These applications enable researchers to detect and quantify SPBC4F6.12 protein expression in cell lysates or tissue samples. The antibody specificity for Schizosaccharomyces pombe makes it particularly valuable for researchers focusing on fission yeast models. When designing experiments, researchers should consider using these validated applications as primary methodologies, while experimental validation would be required for other immunological techniques not explicitly listed.

How does the molecular structure of SPBC4F6.12 influence antibody design?

The LIM domain structure of SPBC4F6.12 presents both opportunities and challenges for antibody design. LIM domains are highly conserved zinc-finger motifs that may share structural similarities with other proteins, potentially affecting antibody specificity. When developing or selecting antibodies against SPBC4F6.12, researchers should consider targeting unique epitopes outside these conserved domains to enhance specificity. Understanding the three-dimensional structure of the protein can guide epitope selection for antibody generation and predict accessibility for antibody binding under various experimental conditions.

What are the critical considerations for Western blot optimization with SPBC4F6.12 antibodies?

For optimal Western blot results with SPBC4F6.12 antibodies, several parameters require careful consideration:

• Sample preparation: S. pombe cells should undergo thorough lysis under conditions that preserve protein integrity. A common approach involves mechanical disruption with glass beads in the presence of protease inhibitors.

• Protein denaturation: Due to the structural characteristics of LIM domain proteins, standard denaturation conditions (95°C for 5 minutes in SDS sample buffer) may be suitable, but optimization might be necessary if aggregation occurs.

• Gel percentage: 10-12% polyacrylamide gels typically provide good resolution for SPBC4F6.12, which has a molecular weight consistent with its amino acid composition.

• Transfer conditions: Standard semi-dry or wet transfer protocols are generally effective, but transfer time and buffer composition may require optimization.

• Blocking and antibody concentration: A 5% BSA or non-fat milk solution is recommended for blocking, with antibody dilutions requiring empirical determination (starting with manufacturer recommendations).

• Detection method: Enhanced chemiluminescence (ECL) or fluorescent secondary antibodies are both compatible, with the choice dependent on the required sensitivity and quantification needs.

Each of these parameters may require laboratory-specific optimization to achieve consistent results with minimal background.

How can researchers validate the specificity of anti-SPBC4F6.12 antibodies?

Antibody validation is a critical step to ensure experimental reliability. For SPBC4F6.12 antibodies, a comprehensive validation approach should include:

• Genetic controls: Using SPBC4F6.12/pxl1 deletion strains as negative controls provides the strongest evidence for antibody specificity.

• Recombinant protein controls: Testing the antibody against purified recombinant SPBC4F6.12 protein can verify recognition of the target protein.

• Peptide competition assays: Pre-incubating the antibody with the immunizing peptide or recombinant protein should eliminate specific signals.

• Cross-reactivity assessment: Testing the antibody against lysates from related yeast species or on mammalian cell lysates to evaluate potential cross-reactivity with homologous proteins.

• Immunoprecipitation followed by mass spectrometry: This approach can identify all proteins recognized by the antibody, confirming whether SPBC4F6.12 is the primary target.

The antibody is considered validated when multiple approaches consistently demonstrate specific recognition of SPBC4F6.12.

What immunoprecipitation protocols are recommended for SPBC4F6.12 research?

Immunoprecipitation of SPBC4F6.12 requires careful consideration of the following methodological aspects:

• Lysis buffer selection: A buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, and protease inhibitors preserves protein-protein interactions while effectively solubilizing membrane-associated proteins like SPBC4F6.12.

• Antibody coupling: Covalent coupling of anti-SPBC4F6.12 antibodies to protein A/G beads using crosslinkers such as BS3 or DMP can prevent antibody co-elution with the target protein.

• Pre-clearing step: Pre-clearing lysates with naked beads reduces non-specific binding.

• Elution conditions: Gentle elution with competing peptides may preserve protein complexes for downstream analysis, while more stringent conditions (e.g., low pH or SDS) increase yield but may disrupt protein-protein interactions.

• Controls: Include both "no-antibody" and "isotype control" samples to distinguish specific from non-specific binding.

The choice between native and denaturing conditions depends on whether the goal is to preserve protein-protein interactions or maximize SPBC4F6.12 recovery.

What sample preparation techniques are optimal for SPBC4F6.12 detection?

Sample preparation techniques must be tailored to both the experimental question and the detection method. For SPBC4F6.12 analysis, consider:

Western Blot Sample Preparation:

• Cell harvesting: Collect mid-log phase cells (OD600 0.5-0.8) for optimal protein expression.

• Cell lysis: Mechanical disruption with glass beads in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, and protease inhibitors.

• Protein quantification: Bradford or BCA assays ensure equal loading across samples.

• Sample denaturation: Heat at 95°C for 5 minutes in Laemmli buffer with β-mercaptoethanol.

Immunofluorescence Sample Preparation:

• Fixation: 3.7% formaldehyde for 30 minutes at room temperature preserves cellular structures while maintaining epitope accessibility.

• Cell wall digestion: Treat with zymolyase (1 mg/ml) to facilitate antibody penetration.

• Permeabilization: 0.1% Triton X-100 for 5 minutes allows antibody access to intracellular antigens.

• Blocking: 3% BSA in PBS for 1 hour reduces non-specific binding.

These protocols should be optimized based on specific experimental requirements and antibody characteristics.

What controls are essential for experiments using SPBC4F6.12 antibodies?

Rigorous experimental design for SPBC4F6.12 antibody-based assays requires the following controls:

Positive Controls:

• Recombinant SPBC4F6.12 protein expressed in E. coli, yeast, or mammalian systems

• S. pombe strains overexpressing SPBC4F6.12/pxl1

• Wild-type S. pombe samples with known SPBC4F6.12 expression patterns

Negative Controls:

• SPBC4F6.12/pxl1 deletion strains

• Secondary antibody-only controls to identify non-specific binding

• Pre-immune serum controls for polyclonal antibodies

Specificity Controls:

• Peptide competition assays where available immunizing peptide blocks specific binding

• Multiple antibodies targeting different epitopes of SPBC4F6.12 to confirm results

• Non-related yeast species without clear SPBC4F6.12 homologs

Including these controls systematically validates experimental findings and distinguishes genuine biological effects from technical artifacts.

How can quantitative analysis of SPBC4F6.12 be performed?

Quantitative analysis of SPBC4F6.12 can be approached through several complementary techniques:

Western Blot Quantification:

• Densitometric analysis using standard curve of recombinant SPBC4F6.12 protein

• Normalization to housekeeping proteins (e.g., α-tubulin or GAPDH)

• Digital image analysis software (ImageJ, Image Studio, etc.) with background subtraction

ELISA-Based Quantification:

• Standard sandwich ELISA using capture antibody, sample, and detection antibody

• Comparison to standard curve generated with purified recombinant SPBC4F6.12

• Absorbance measurements at appropriate wavelengths (typically 450 nm)

Quantitative Microscopy:

• Immunofluorescence with consistent image acquisition parameters

• Measurement of fluorescence intensity in defined cellular regions

• Single-cell analysis to account for heterogeneity in expression

For all methods, technical replicates (minimum n=3) and biological replicates are essential for statistical validity. Data should be presented with appropriate statistical analysis, including measures of central tendency and dispersion.

How does SPBC4F6.12/Pxl1 function relate to other LIM domain proteins in yeasts?

SPBC4F6.12/Pxl1 belongs to the family of LIM domain-containing proteins that are highly conserved across eukaryotes. In fission yeast, several other LIM domain proteins exist, including Pax1 and Rga8, which function in cell polarity and morphogenesis. Comparative studies between SPBC4F6.12 and other LIM domain proteins reveal:

• Structural similarities in zinc-finger motifs that mediate protein-protein interactions

• Functional differences in subcellular localization and binding partners

• Overlapping but distinct roles in cytoskeletal organization and cell division

Research approaches to elucidate these relationships include:

• Systematic yeast two-hybrid screens to identify interaction partners

• Co-immunoprecipitation experiments using SPBC4F6.12 antibodies followed by mass spectrometry

• Genetic interaction studies through synthetic lethality/sickness screens

• Comparative localization studies using fluorescently tagged proteins

Understanding these relationships contributes to a systems-level view of how LIM domain proteins coordinate cellular processes in evolutionarily diverse organisms.

What role do post-translational modifications play in SPBC4F6.12 function and antibody recognition?

Post-translational modifications (PTMs) of SPBC4F6.12 can significantly impact both its biological function and antibody recognition. Common PTMs that may affect SPBC4F6.12 include:

• Phosphorylation: LIM domain proteins are frequently regulated by phosphorylation, particularly in response to cell cycle progression or environmental stresses

• Ubiquitination: May regulate protein turnover and function

• SUMOylation: Often affects protein-protein interactions and subcellular localization

These modifications can create challenges for antibody-based detection:

• Modification-specific epitopes may be recognized by some antibodies but not others

• Certain PTMs may mask epitopes, reducing antibody binding efficiency

• The PTM status may vary based on cellular conditions, leading to inconsistent detection

Researchers should consider these factors when selecting antibodies and interpreting results. Techniques such as Phos-tag SDS-PAGE and modification-specific antibodies can help characterize the PTM landscape of SPBC4F6.12 under different experimental conditions.

How can CRISPR-Cas9 genome editing be utilized in SPBC4F6.12 antibody validation?

CRISPR-Cas9 technology provides powerful approaches for antibody validation through precise genetic manipulation of SPBC4F6.12:

Complete Gene Knockout Approach:

• Design sgRNAs targeting the SPBC4F6.12/pxl1 coding sequence

• Replace the coding sequence with a selection marker through homology-directed repair

• Confirm deletion through PCR and sequencing

• Test cell lysates from wild-type and knockout strains with the antibody

Epitope Tagging Approach:

• Design sgRNAs and repair templates to add an epitope tag (FLAG, HA, etc.) to the endogenous SPBC4F6.12

• Screen for successful integration through PCR and sequencing

• Perform parallel detection with anti-SPBC4F6.12 and anti-tag antibodies

• Compare localization patterns and expression levels

Point Mutation Approach:

• Introduce specific mutations to alter the antibody epitope

• Test antibody recognition of the mutated protein

• Confirm expression of the mutated protein using alternative detection methods

These approaches provide definitive evidence for antibody specificity and can also generate valuable research tools for further functional studies of SPBC4F6.12.

What are common challenges when using anti-SPBC4F6.12 antibodies and how can they be addressed?

When working with anti-SPBC4F6.12 antibodies, researchers may encounter several technical challenges:

High Background in Western Blots:

• Increase blocking time or concentration (5% BSA or milk)

• Reduce primary antibody concentration

• Increase washing stringency with higher salt concentration (up to 500 mM NaCl)

• Try alternative blocking agents (casein, fish gelatin)

Weak or No Signal:

• Increase protein loading (up to 50 μg per lane)

• Reduce washing stringency

• Extend primary antibody incubation (overnight at 4°C)

• Test alternative extraction buffers to improve protein solubility

• Verify protein expression using RT-PCR as a complementary approach

Multiple Bands or Unexpected Band Size:

• Use freshly prepared samples with complete protease inhibitor cocktails

• Include phosphatase inhibitors to preserve native protein state

• Compare with recombinant protein control

• Perform peptide competition assay to identify specific bands

Poor Reproducibility:

• Standardize lysate preparation protocol

• Use consistent antibody lots when possible

• Prepare aliquots of antibody to avoid freeze-thaw cycles

• Document detailed experimental conditions for each experiment

Systematic troubleshooting combined with appropriate controls will help resolve most technical issues encountered with anti-SPBC4F6.12 antibodies.

How can cross-reactivity issues with anti-SPBC4F6.12 antibodies be assessed and mitigated?

Cross-reactivity assessment is crucial for ensuring experimental specificity when using anti-SPBC4F6.12 antibodies:

Assessment Methods:

• Testing against closely related yeast species (S. cerevisiae, C. albicans)

• Testing against known homologs in other organisms

• Immunoprecipitation followed by mass spectrometry identification of all bound proteins

• Comparison of staining patterns in wild-type and SPBC4F6.12 knockout strains

Mitigation Strategies:

• Pre-absorption of antibodies with lysates from species lacking SPBC4F6.12 homologs

• Affinity purification against recombinant SPBC4F6.12 protein

• Use of monoclonal antibodies targeting unique epitopes

• Competitive elution with immunizing peptides to recover only specific antibodies

The ideal approach combines careful assessment of potential cross-reactivity followed by strategic mitigation based on experimental requirements and available resources.